Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth

“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.